Polio - Pipeline Review, H2 2015

Date: November 30, 2015
Pages: 69
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PF8C36F8FD0EN
Leaflet:

Download PDF Leaflet

Polio - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Polio - Pipeline Review, H2 2015’, provides an overview of the Polio’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polio, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polio and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Polio
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Polio and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Polio pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Polio
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Polio pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Polio Overview
Therapeutics Development
Pipeline Products for Polio - Overview
Pipeline Products for Polio - Comparative Analysis
Polio - Therapeutics under Development by Companies
Polio - Therapeutics under Investigation by Universities/Institutes
Polio - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Polio - Products under Development by Companies
Polio - Products under Investigation by Universities/Institutes
Polio - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
Bharat Biotech International Limited
Biological E. Limited
Boryung Pharmaceutical Co., Ltd.
Codagenix, Inc.
Crucell N.V.
Daiichi Sankyo Company, Limited
Grifols, S.A.
Panacea Biotec Limited
Sanofi Pasteur SA
Sentinext Therapeutics Sdn Bhd
Sinovac Biotech Ltd.
Taiga Biotechnologies, Inc.
Polio - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPVGVI-3000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio (bivalent) virus like particle vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio (monovalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio [sabin] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
polio vaccine [types 1, 2, 3] (monovalent) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
poliomyelitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PR-5I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protein for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VN-0105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polio - Recent Pipeline Updates
Polio - Dormant Projects
Polio - Discontinued Products
Polio - Product Development Milestones
Featured News & Press Releases
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Polio, H2 2015
Number of Products under Development for Polio - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Polio - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
Polio - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2015
Polio - Pipeline by Bharat Biotech International Limited, H2 2015
Polio - Pipeline by Biological E. Limited, H2 2015
Polio - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015
Polio - Pipeline by Codagenix, Inc., H2 2015
Polio - Pipeline by Crucell N.V., H2 2015
Polio - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Polio - Pipeline by Grifols, S.A., H2 2015
Polio - Pipeline by Panacea Biotec Limited, H2 2015
Polio - Pipeline by Sanofi Pasteur SA, H2 2015
Polio - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2015
Polio - Pipeline by Sinovac Biotech Ltd., H2 2015
Polio - Pipeline by Taiga Biotechnologies, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Polio Therapeutics - Recent Pipeline Updates, H2 2015
Polio - Dormant Projects, H2 2015
Polio - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Polio, H2 2015
Number of Products under Development for Polio - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015
Skip to top


Polio - Pipeline Review, H1 2015 US$ 1,600.00 Apr, 2015 · 63 pages
Malignant Glioma - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 87 pages
Heart Attack - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 46 pages

Ask Your Question

Polio - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: